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, and Maria Consuelo Pina-Pérez
†7 
Currently, Helicobacter pylori is a unique biological carcinogenic agent. The search for antimicrobial alternatives to 
antibiotics against this pathogen has been categorized as a priority due to the drastic failure associated with  current 
applied antibiotic therapy. The present study assessed the bioactive antimicrobial capability of fucoidan (“Generally 
Recognized as Safe” approval – European Commission December 2017)1 from different species of Phaeophyceae algae 
(Fucus vesiculosus, Undaria pinnatifida, Macrocystis pyrifera) against H. pylori. All studied fucoidans showed bacteriostatic 
and bactericidal effects at the studied concentrations [5-100] µg/ml, and exposure times [0-7] days. The most effective 
anti-H. pylori fucoidan was validated in Caenorhabditis elegans as an in vivo model. C. elegans feed was supplemented 
with Undaria pinnatifida [0-100] µg/ml fucoidan, resulting in a significant improvement in  lifespan, lowered H. pylori 
concentration in  digestive tract, and increased egg-laying pattern. New research lines proposing this compound as active 
agent in nutraceutical and preventive novel therapies should be opened.
Introduction  1 
Nowadays, Helicobacter pylori is one of the most important 2 
emerging human pathogens. Although the routes of 3 
transmission from the environment to humans are not 4 
completely defined, the entrance of H. pylori into the food 5 
chain has been identified as one of the dissemination 6 
pathways. 
2
 To date, DNA of H. pylori has been found mainly in 7 
water, raw milk, meat products and fresh salads, and the H. 8 
pylori prevalence values range from 2-30 % depending on the 9 
considered product. 
3-5
  10 
H. pylori invades the gastric mucosa and infects humans 11 
producing several digestive tract disorders, such as chronic 12 
active gastritis, peptic ulceration, and in severe cases, gastric 13 
cancer. This organism was definitively classified as the unique 14 
biological carcinogenic agent in 1994.
6
 One of the most 15 
concerning points regarding the eradication of this pathogen is 16 
the critical resistance that H. pylori has developed in recent 17 
years against the current antimicrobial applied therapies (the 18 
effectiveness has decreased to 70 % compared  to other 19 
antibiotic therapies against other infectious pathogens  that 20 




Under the urgent claim of the World Health Organization in 24 
2017 to find alternative antimicrobial strategies to fight against 25 
the most resistant human pathogens,
6
 novel natural 26 
antimicrobials have been investigated. In that sense, several 27 
compounds of  vegetable and animal origin have shown 28 
antimicrobial capability against H. pylori, some of which were 29 
used from ancient times to avoid gastrointestinal problems.
7
 30 
The effect of lactoferrin from bovine milk against H. pylori was 31 
studied by Di Mario et al., (2003)
10
. This compound showed a 32 
synergistic effect against H. pylori proliferation in vivo used in 33 
combination with antibiotics. Catechins from green tea, and 34 
quercetin glycosides from apple peel, have shown strong anti-35 
urease activity affecting H. pylori membrane functionality. 
11,12
 36 
Recently,  propolis from the honeybee Apis mellifera has also 37 
been identified as an effective compound against this 38 
pathogen  with a chemoprotective effect on gastric epithelial 39 
cells.
13
 In addition, phenolic compounds have been suggested 40 
to have  a great antimicrobial potential against H. pylori.
14,15
 41 
Additional  studies regarding the mechanism of polyphenol 42 
action inhibiting H. pylori growth have indicated that under 43 
exposure to these antimicrobial phytochemicals, H. pylori 44 
enters in coccoid form, remaining unable to grow. Terpenes 45 
from essential oils and phenolic compounds from ginger have 46 
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Since the last 10 years, novel advances regarding the influence 49 
of the gastrointestinal microbiome on H. pylori inhibition, and 50 
on individual and population-based gastric cancer prevention 51 
strategies, have been studied.
18
 Compounds of  marine origin  52 
have recently been used as ingredients with high applicability 53 




algae constitutes a sustainable source of bioactive 55 
molecules, with brown algae from the Phaeophyceae group 56 
primarily rich in complex carbohydrates, with high prebiotic, 57 
immune-modulator and antioxidant potential.
22, 23
  58 
Among them, the complex fucoidan,  sulphated polysaccharide 59 
of brown algae, has been described to significantly encourage 60 
the growth of beneficial intestinal microbiota, stimulates the 61 
immune system; and inhibit the viral replication; and has  62 
antioxidant, anti-inflammatory and anticancer properties,
23,24
 63 
hence fucoidan has been named as  “nutrient of the future”
25, 64 
26
. According to the review of Morya et al., (2012),
27
 since 65 
fucoidan was first isolated in 1918, more than eight hundred 66 
articles focusing on fucoidan have been cited in PUBMED. 67 
Although, fucoidan extracts from algae have not been 68 
approved for use in biomedical applications, research on the  69 
bioactivity of this compound has increased exponentially in 70 
recent years (e.g. as promising agents in drug delivery, 71 
biomaterials, topical agents, and orally delivered agents for a 72 
variety of pathologies)
28
. Fucoidan has the status of generally 73 
recognized as safe “GRAS” in the USA, Canada, Australia, and 74 
recently in Europe (approval December 2017).
29 
However, to 75 
our knowledge only one previous publication has addressed 76 
the in vivo evaluation of fucoidan as a possible anti-H. pylori 77 
agent. 
30
 Recently, the nematode Caenorhabditis elegans has 78 
been incorporated as a whole animal screening platform for 79 
antimicrobials.
31-33
 This organism has a rapid generation time 80 
(300 genetically identical progeny in a 3-day life cycle). The 81 
entire genome of this self-fertilizing hermaphrodite nematode 82 
has been sequenced. Caenorhabditis elegans, is an 83 
invertebrate animal model that has  a high homology to the 84 
human genome and mimics human physiological responses.
34
 85 
Using this novel model, Moy et al., (2009)
35
 tested more than 86 
40,000 compounds and extracts, and  identified 28 novel 87 
antimicrobials against Enterococcus faecalis and Candida 88 
albicans. In fact, many of the virulence factors involved in the 89 




The aim of the present study is to evaluate the in vitro and in 92 
vivo antimicrobial potential of fucoidan against H. pylori, by 93 
testing the effectiveness of fucoidan from three different 94 
Phaeophyceae species, Fucus vesiculosus, Macrocystis pyrifera, 95 
and Undaria pinnatifida. The origin and concentration of 96 
fucoidan were evaluated in terms of bacteriostatic and 97 
bactericidal potential, and the protective effect of fucoidan 98 
against H. pylori proliferation was assessed in vivo using 99 
Caenorhabditis elegans model. The obtained results could 100 
contribute to the future development of promising human 101 
therapies anti-H. pylori.  102 
Material and Methods 103 
Helicobacter pylori bacterial culture 104 
The strain of H. pylori used in the present study was provided 105 
by the United Kingdom Culture Type Collection with reference 106 
number 11637 NCTC. The lyophilized culture was revived 107 
according to the protocol provided by the NCTC. Cells were 108 
grown under optimal conditions (37 °C, microaerobic 109 
conditions: O2 5 %; CO2 15 %; N2 85 %) in liquid Brucella Broth 110 
medium (BB) (B3051 Sigma-Aldrich; Merck KGaA, Darmstadt, 111 
Germany) supplemented with 5 % (v/v) sterile foetal  Bovine 112 
Serum (FBS) for 5-7 days until the stationary phase was 113 
reached.
37,38
 Cells recovered by centrifugation were  washed 114 
three times with 5 % BB-FBS; homogenized aliquots were 115 
placed into Eppendorf tubes (2 ml) and preserved at  -80 C 116 
until use. The final concentration of the culture stock was 117 
1±0.54x10
8
 CFU/ml. 118 
 119 
Fucoidan extracts 120 
Fucoidan extracts included in the present study (purity≥95 %) 121 
were provided as powders by Merck KGaA International 122 
Company (Darmstadt, Germany) and included: Fucus 123 
vesiculosus (F8190 Sigma; molecular weight 82 kDa; sulfate 124 
content 24.5 % (w/w); most abundant monosaccharides: 125 
mannose (1.27 %),  fucose (38 %),  and galactose (3 %)); 126 
Macrocystis pyrifera (F8065 Sigma; molecular weight 176 kDa; 127 
sulfate content 27 % (w/w); most abundant monosaccharides: 128 
mannose (1.12 %), fucose  (26 %), and galactose (4 %)); and 129 
Undaria pinnatifida (F8315 Sigma; molecular weight 51 kDa; 130 
sulfate content 30 % (w/w); most abundant monosaccharides: 131 
mannose (5 %), fucose (39 %), and galactose (27 %))
39
.  132 
 133 
Fucoidan antimicrobial suspensions 134 
For each of the considered Phaeophyceae species, a stock 135 
solution at concentration of 5000 µg/mL was prepared in 136 
Müeller Hinton broth (MHB) (70192 Sigma-Aldrich; Merck 137 
KGaA International Company (Darmstadt, Germany)). For each 138 
of the independent trials, the suspensions were aliquoted in 2 139 
ml Eppendorf tubes and stored at -20 °C for use.  140 
Suspensions of fucoidan at concentrations of 5, 10, 25, 50 and 141 
100 µg/ml were prepared in 10 ml tubes containing MHB+FBS 142 
(5 %) from the initial 5000 µg/ml stock. Liquid media MHB+FBS 143 
(5 % no-supplemented with fucoidan) was used as the control 144 
broth.  145 
 146 
Inoculation and microbial analysis 147 
H. pylori stock cells were revived under optimal conditions. 148 
Stocks of bacterial solution (100 µl) was spread on plates of 149 
Columbia blood agar (CBA, Difco, Franklin Lakes, New Jersey, 150 
USA) supplemented with defibrinated horse blood (10 %) (HB, 151 
Oxoid, UK) (CBA+HB 10 %) and incubated at 37 °C under 152 
microaerobic conditions. Seven-day-old cultures were 153 
harvested by scraping the bacterial growth with a sterile swab. 154 
Recovered cells were resuspended in both (i) MHB+FBS 5 % 155 
without fucoidan (considered as a control of bacterial growth) 156 
and; (ii) MHB+FBS 5 % with [5-100] µg/ml fucoidan 157 
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suspensions. In both cases the initial optical density (OD) at λ = 158 
600 nm was fitted to 0.10±0.05.  159 
The effect of fucoidan on the microbial growth / inhibition of 160 
H. pylori at 25 °C was registered by measuring  OD600 nm (at 161 
regular time intervals, 12-24h) using a Biomate 3 (Thermo 162 
Scientific, S.A.) spectrophotometer.  Additionally, for each time 163 
interval, 100 µl aliquots were also taken in duplicate from each 164 
suspension (supplemented / not supplemented with fucoidan). 165 
Serial 10-fold dilutions of all aliquots were prepared in sterile 166 
PBS solution (1X (130 mmol/l sodium chloride, 10 mmol/l 167 
sodium phosphate, pH 7.2)), and seeded on CBA+HB (10 %) 168 
plates. Plates were incubated at 37 °C for 5-7 days under 169 
microaerobic conditions in anaerobic jars (Campy Gas Pak 170 
system; Oxoid, Basingstoke, UK) prior to bacterial counting.  171 
All suspensions prepared in the present study were replicated 172 
without bacterial inoculation, and were considered as the 173 
blank for the OD measurements. These suspensions were 174 
incubated at 25 °C, under microaerobic conditions, to assess 175 
possible background contamination during the process.  176 
 177 
Caenorhabditis elegans strain and growth conditions  178 
C. elegans strain N2 was obtained from the College of 179 
Biological Sciences, Minnesota University, USA.  Agar plates 180 
containing Nematode Growth Medium (NGM) were used to 181 
maintain nematodes (25°C) that were fed on a bacterial lawn 182 
of E. coli OP50.
40 183 
NGM plates supplemented with fucoidan were prepared. The 184 
most effective fucoidan according to in vitro studies was 185 
selected for the in vivo validation assay, which included NMG 186 
plates prepared with fucoidan at concentrations ranging from 187 
[5-100] µg/ml.  To validate the protective capability of 188 
fucoidan against the invasion and infection of H. pylori in 189 
nematodes, age-synchronized nematodes were distributed on 190 
NGM+fucoidan plates on a bacterial lawn of H. pylori (10
4
 log10 191 
cycles per plate). The lifespan and egg-laying of C. elegans, and 192 
the H. pylori concentration in the digestive tract of the 193 
nematode were evaluated in nematodes grown  on  NMG 194 
plates seeded with H. pylori (considered as control), and 195 
nematodes grown on NMG+fucoidan plates.  196 
 197 
The worms were maintained at 25 °C during their life cycle 198 
(approximately three weeks) and were examined at 24 h 199 
intervals for lifespan studies (10 nematodes per plate/ 5 200 
repetitions). Nematodes were transferred every day to fresh 201 
plates prepared with NGM or NGM+fucoidan and seeded with 202 
H. pylori (10
4
 log10 cycles per plate). Worms were considered 203 
dead when they did not move and did not respond to 204 
stimulation (contact with a platinum worm picker).  205 
For fertility analysis, first-stage larvae (L1) were transferred to 206 
fresh bacterial lawns (E. coli OP50 reference; and H. pylori 207 
control) in NGM, individually (25 replicates in 5 individual 208 
repetitions) marking the start of the experiment (time t = 0). 209 
Nematodes were transferred every day to fresh plates for the 210 
whole lifecycle of the nematode. Egg-counting was carried out 211 
every 6 h (3 times per day). The same procedure was carried 212 
out for nematodes fed with H. pylori on NGM plates 213 
supplemented with fucoidan at different concentrations. The 214 
reproductive success (RS) was measured as the total number 215 
of viable eggs laid per day by nematodes in each cohort (125 216 
individual evaluated nematodes for each scenario).  217 
Additionally, the H. pylori concentration (CFU per nematode) 218 
in the digestive tract of nematodes was quantified by real time 219 
quantitative polymerase chain reaction qRT-PCR assay.  220 
 221 
Helicobacter pylori quantification by real time - quantitative 222 
polymerase chain reaction (qRT-PCR) based on SYBR green I 223 
fluorescence  224 
For quantification assays (concentration of H. pylori in the  225 
digestive tract during C. elegans feeding), 5 age-synchronized 226 
nematodes were placed on a plate (NGM medium or 227 
NGM+fucoidan medium);  10 plates per assay condition, and 5 228 
repetitions per scenario were used. Nematodes were 229 
transferred every 24h to freshly prepared plated during their 230 
complete life cycle. Grown  nematodes were recovered from 231 
plates at different intervals (0, 1, 3, 5, 8, 10, 12, and 15 days) 232 
and washed in drops containing 5 μl  of 25 mM levamisole in 233 
M9 buffer (LM buffer) for paralysis and inhibition of 234 
pharyngeal pumping and expulsion.
41
 Then LM buffer was used 235 
to wash the nematodes twice more. Afterwards, the washed 236 
nematodes were placed in a 1.5 ml Eppendorf tube containing 237 
50 μl of PBS buffer with 1% Triton X-100 and mechanically 238 
disrupted using a motor pestle. Nucleic acids were extracted 239 
from worm lysates using the GeneJet™ Genomic DNA 240 
Purification Kit (Fermentas, Baden-Württemberg, Germany) 241 
following the mammalian tissue protocol, according to the 242 
manufacturer's instructions. Helicobacter DNA was detected 243 
using a LightCycler
®
 2.0 Instrument (Roche Applied Science, 244 
Spain) according to the optimized qRT-PCR approach 245 
developed by Pina-Pérez et al., (2018). 
42 246 
 247 
Statistical analysis 248 
The significance of fucoidan antimicrobial potential against H. 249 
pylori was assessed by evaluating studied variables through  250 
ANOVA. To determine which levels of each factor were 251 
significantly different (p ≤ 0.05) a multiple range test (MRT) 252 
was applied, and the Fisher distribution (LSD) was used to 253 
check equality of variances. Statgraphics
®
 Centurion XV 254 
software (Statpoint Inc., Virginia, USA) was used for all the 255 
statistical analyses carried out in the present study.  256 
Results  257 
In vitro antimicrobial potential of fucoidan from Phaeophyceae 258 
species against H. pylori 259 
Figure 1 shows the kinetic behaviour of H. pylori at 25 °C, in 260 
the control reference liquid medium MHB+FBS (5 %) and in 261 
media supplemented with fucoidan at different 262 
concentrations. As seen graphically, the highest antimicrobial 263 
effects are shown for the high fucoidan concentrations 264 
applied, independent of the fucoidan origin. Moreover, under 265 
the same incubation conditions and concentrations applied, 266 
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the origin of fucoidan significantly affected (p-value ≤0.05) the 267 
bactericidal/bacteriostatic effect exerted against H. pylori. 268 
Table 1 includes the fucoidan concentrations required to exert 269 
a bacteriostatic or bactericidal effect against H. pylori 270 
depending on the origin species.  271 
Fucoidan [5-100] µg/ml from Undaria pinnatifida resulted in 272 
the most effective reduction in H. pylori bacterial counts 273 
(bacterial count reduction ≈ 2 to 4 log10 cycles). At this 274 
incubation temperature (25°C), fucoidan from Macrocystis 275 
pyrifera at concentrations in the range of [50-100] µg/ml 276 
effectively inhibited  bacterial growth showing bacteriostatic 277 
effects. The values of the final bacterial load  remained close 278 
to the initial bacterial load inoculated  (≈4.25±0.077 log10 279 
cycles). During the first 5 days of incubation, [50-100] µg/ml 280 
fucoidan from Macrocystis pyrifera  effectively inhibited  2.70 281 
log10 cycles of  H. pylori. Additionally, cell exposure to 100 282 
µg/ml  fucoidan from Macrocystis pyrifera resulted in no viable 283 
culturable (VC) forms of H. pylori after 7 days of incubation. 284 
Two hypothesis can be proposed based on this result:  (i) due 285 
to the stressful effect that fucoidan causes on H. pylori cells, 286 
the cells become in a coccoid form (viable but not culturable, 287 
VBNC), or (ii) due to the bactericidal effect of the fucoidan, 288 
cells become inactivated .  289 
Fucoidan from Fucus vesiculosus presented a high 290 
antimicrobial effect against the H. pylori population, with the 291 
lowest concentrations from [5-10] µg/ml  to control bacterial 292 
growth, exerting a significant bacteriostatic effect; 2.80±0.07 293 
log10 cycles inhibition was observed with 10 µg/ml (7 days, 25 294 
C). The antimicrobial effect of fucoidan from Fucus 295 
vesiculosus was bactericidal at concentrations in the range of 296 
[25-100] µg/ml. The higher the concentration of fucoidan, the 297 
faster the microbial inactivation was (p-value ≤ 0.05); [50-100] 298 
µg/ml was able to reduce the bacterial load  1.60±0.15 and 299 
2.60±0.24 log10 cycles, respectively, after just 24 h of microbial 300 
exposure. After 3 days of exposure to fucoidan from Fucus 301 
vesiculosus, 3.55±0.28 log10 cycles of microbial inactivation 302 
were achieved in suspensions containing 100 µg/ml fucoidan.  303 
According to our results, fucoidan from brown algae Undaria 304 
pinnatifida was the most effective against H. pylori at 25 °C. 305 
Taking into account the exposure of bacterial cells to fucoidan, 306 
after 24 h of incubation, concentration levels in the range of 307 
50-100 µg/ml showed bactericidal effects. After 48 h of 308 
exposure, concentrations in the range of 25-50 µg/ml achieved 309 
a reduction of 2.30±0.25 log10 in the VC population of H. pylori.  310 
The concentration of 100 µg/ml was completely effective in 311 
reducing the H. pylori VC cells to below the detection limit 312 
(bactericidal effect = 4.10±0.12 log10 cycles). Even at low 313 
concentrations [10-25] µg/ml, fucoidan from Undaria 314 
pinnatifida showed bactericidal effects, being able to reduce 315 
the VC population of H. pylori from 4.85±0.12 to 6.85±0.24 316 
log10 cycles with respect to the control, after 7 days of 317 
exposure at 25 C.  318 
An ANOVA analysis was performed to determine the 319 
significance of the studied factors in reducing the level of H. 320 
pylori. The fucoidan  origin (p value ≤ 0.05); concentration,  (p 321 
value ≤ 0.05); and exposure time (p value ≤ 0.01) were 322 
significant factors affecting the antimicrobial capability of this 323 
bioactive compound.  324 
For all the studied conditions, and considering the three 325 
Phaeophyceae species included in the present research, it can 326 
be concluded that the higher the exposure time of bacterial 327 
cells to fucoidan, the higher the antimicrobial effect exerted by 328 
each of the considered fucoidan suspensions. Moreover, the 329 
higher the concentration of fucoidan present in liquid media, 330 
the higher the reduction of VC counts of H. pylori,  [50-100] 331 
µg/ml of fucoidan was always effective and completely 332 
reduced (≈3.39-4.48 log10 cycles) the bacterial counts, in 2-7 333 
days depending on fucoidan origin.  334 
 335 
Caenorhabditis  elegans as a model for Helicobacter pylori 336 
infection: validation of the protective effect of fucoidan  337 
Fucoidan from Undaria pinnatifida was selected to test the in 338 
vivo antimicrobial potential of this compound using the C. 339 
elegans model. Figure 2 shows the survival function of C. 340 
elegans fed with H. pylori in NGM medium and NGM medium 341 
supplemented with fucoidan at different concentrations. As  342 
seen graphically, there was a significant increase in the survival 343 
capability of the nematode fed with H. pylori in the presence 344 
of fucoidan, even when this compound was  added at the 345 
lowest concentrations (5 µg/ml). Meanwhile, the bactericidal 346 
potential of fucoidan was exerted in vitro in the concentration 347 
range of 50-100 µg/ml, in the in vivo assay, 5 µg/ml of fucoidan 348 
from Undaria pinnatifida was effective in increasing the 349 
lifespan of C. elegans, from 10 days in NGM (C. elegans fed 350 
with H. pylori) to 17 days in NGM + 5 µg/ml fucoidan. The 351 
addition of fucoidan at a concentration ≥25 µg/ml increased 352 
the lifespan of the nematode (26±2 days) even more than the 353 
lifespan observed in the reference (23 days lifespan when C. 354 
elegans in NGM was fed with optimal E. coli OP50).  355 
Regarding the fertility assay, C. elegans N2 fed with E. coli 356 
OP50 in NGM (reference conditions) showed an RS equal to 357 
155±23 eggs laid per day in the first 7 days, with egg-laying 358 
significantly reduced from day 5 of the life cycle.  Under the H. 359 
pylori feeding pattern in NGM, the nematodes egg-laying was 360 
interrupted just after the first 36 h, and in many cases, worms 361 
retained eggs in bag  (36 out of 125). The number of viable 362 
offspring was also reduced significantly in nematodes fed with 363 
H. pylori in relation to nematodes fed under reference 364 
conditions (E. coli OP50) (Table 2). Working with NGM 365 
supplemented with fucoidan at different concentrations, the 366 
reproductive timing of C. elegans was extended (5-12 days) 367 
and additionally, the number of laid eggs was increased, which 368 
was directly related to the concentration of fucoidan added to 369 
the media (see Table 2).  370 
 371 
To establish a relationship between C. elegans infection 372 
(reduced lifespan and reduced egg laying) and H. pylori 373 
accumulation in the digestive tract, H. pylori was quantified 374 
across the lifespan of the nematode by qRT-PCR. Table 3 375 
shows the quantitative values detected for H. pylori depending 376 
on considered scenarios. C. elegans fed with H. pylori seeded 377 
in NGM medium showed an increase in the intestinal load  378 
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from < 10
2
 H. pylori CFU/worm on day 0 (L4 stage) to 10
5
 379 
CFU/worm on  day 7, and  only 12 % of the initial population 380 
was able to survive. Nematodes grown on NGM+ fucoidan 381 
plates showed < 10 
2
 H. pylori CFU/worm under ≥ 10 µg/ml 382 
fucoidan exposure, with no significant differences between 383 
digestive colonization of C. elegans when fucoidan was added 384 
in the range 10-100 µg/ml.  385 
Discussion 386 
Fucoidans from Phaeophyceae have been described to be 387 
more effective as antitumoural agents than other fucoidans 388 
from other algae species, even more, fucoidans from 389 
Phaeophyceae have a wide spectrum of functionalities not 390 
attributed to other fucoidans.
23,24,43 
 The present study 391 
concludes the significant differences between the fucoidans 392 
from three species of Phaeophyceae evaluated for their 393 
antimicrobial capability against H. pylori. Although the 394 
fucoidans resulted in all cases effective exerting both 395 
bacteriostatic and bactericidal effects 
44
, fucoidan from 396 
Undaria pinnatifida was the most effective, with bactericidal 397 
potential even at the lowest concentrations [5-10] µg/ml, 398 
depending on the exposure time. Previous studies outlined 399 
different bioactivities associated with fucoidans derived from 400 
different species, and additional  bioactive potentials for 401 
fucoidan fractions derived from the same species have been 402 
observed 
26,45 
depending on the molecular weight (high or low) 403 
of fucoidan.
46,47,48
 The specific bioactivities exerted by fucoidan 404 
have been mainly associated to the structure of fucoidan 405 
molecules and fucose groups.
49,50
 According to Mak et al., 406 
(2014)
49 
the selective cytotoxicity of fucoidan against cancer 407 
cells has been related to the sulfate content, uronic acid 408 
content, and molecular weight of different fucoidan fractions 409 
50
. However, scarce information has been published regarding 410 
the relationship that exists between fucoidan structure and 411 
the bioactivity of these molecules.  412 
  413 
Specifically, the antimicrobial effects of sulfated 414 
polysaccharides against H. pylori have been described as 415 
multimodal actions (mainly, reinforcement of adaptative 416 
immunity cells and antioxidant effects). 
51,52,53
 The anti-417 
Helicobacter pylori effect of sulfated polysaccharides was 418 
previously reviewed by Besednova et al. (2015). 
51
 According to 419 
Besednova et al. conclusions, sulfated polysaccharides from 420 
Phaeophyceae demonstrated in vitro anti-ulcer effects, 421 
prevention of the adhesion of H. pylori to gastric cells, and 422 
reduction in the H. pylori capability to from biofilms. Fucoidan 423 
concentrations in the range 100-1000 µg/ml are required in 424 
vitro to show anti-H. pylori significant effects. 
52
  425 
 426 
In the present study, the in vitro and in vivo concentration 427 
levels of fucoidan showing bactericidal potential against H. 428 
pylori were very low for Undaria pinnatifida (5-100 µg/ml)-. 429 
Previous studies by Chua et al., (2015)
52
 revealed that fucoidan 430 
from Undaria pinnatifida reduced the adherence of H. pylori to 431 
human gastric adenocarcinoma epithelial cells (AGS) when 432 
added at a concentration of 100 µg/ml. Also, Palanisamy et al. 433 
(2017)
24
 showed significant antimicrobial effects of fucoidan 434 
from Spatoglossum asperum at concentrations in the range 435 
100-150 µg/ml. Furthermore, Lee et al., (2013)
54-
 previously 436 
demonstrated the synergistic effect of fucoidan in combination 437 
with antibiotics, reducing oral pathogenic bacteria. However, 438 
no previous study detected a reduction in H. pylori 439 
proliferation in culture (bacteriostatic or bactericidal effect) 440 
during an exposure time of 24-48 h. In contrast, and according 441 
to the results obtained  in the present study, it was 442 
demonstrated that the  antimicrobial potential of fucoidan 443 
against H. pylori was  significantly enhanced by both, the 444 
fucoidan concentration added to the medium, and the 445 
exposure time (0-7 days). According to the results of Mak et 446 
al., (2014)
50
, the addition of 100 µg/ml fucoidan from Undaria 447 
pinnatifida to the medium   dislodged H. pylori from host cell 448 
surface. Combining the results from both studies, it is possible 449 
to infer that under the correct dosage, novel drug 450 
development can be carried out, including fucoidan as  451 
complement to antibiotics in the treatment of H. pylori 452 
infection, with the effectiveness of the treatment optimized 453 
based on the ingested fucoidan concentration (anti-adherence 454 
/ anti-proliferation / and killing effects on H. pylori), and also 455 
based to treatment exposure time. 
50,51,52,54 456 
Bioactive compounds from algae have also been tested in vivo 457 
using the C. elegans model.
55,56,57
 During its growth, the worm 458 
intakes nutrients from the medium, in addition  to the 459 
ingestion of the bacterial food source (E. coli OP50 or H. pylori 460 
in this case). Methanolic extracts from red alga, Chondrus 461 
crispus, have been demonstrated to increase the C. elegans 462 
lifespan increasing the oxidative stress tolerance of the 463 
nematode.
56 
 Astaxanthin (AX) from marine origin has  also 464 
been described with high impact, increasing the lifespan of C. 465 
elegans populations fed on medium supplemented with 0.1 to 466 
1 mM  AX  by 16-30 % (E. coli OP50 as food source).
54
 In the 467 
present study, under fucoidan intake, the ingestion of H. pylori 468 
was reduced and the resistance of the nematode to this 469 
pathogen was improved (longer lifespan, improved fertility 470 
rate). Under fucoidan ingestion, C. elegans recovered the 471 
capability to  grow even in the presence of H. pylori, up to 472 
levels corresponding to the pattern of nematodes fed E. coli 473 
OP50. Similar results were detected for the fertility assays; 474 
increasing the RS was increased close to 5-fold due to the 475 
addition of  100 µg/ml fucoidan to the media addition to the 476 
media. Confirming the lower values of H. pylori present in the 477 
nematode fed under fucoidan exposure, it was assumed that 478 
there was a possible combined protective effect between the 479 
antioxidant and fucoidan by signaling specific defense 480 
pathways in the nematode (e.g avoiding the ingestion of H. 481 
pylori) and the effective antibacterial potential of this 482 
compound exerted on H. pylori cells (anti-adherence and 483 
bactericidal activity at the in vivo level).
53,54
 According to Ewald 484 
(2018)
56
, reactive oxygen species (ROS) and antioxidant intake 485 
homeostasis are important for extracellular matrix integrity, 486 
pathogen defense, oxidative stress resistance, and longevity in 487 
C. elegans, probably explaining the synergy between fucoidan 488 
effects (the direct antioxidant potential, pathogen defense and 489 
antimicrobial specific potential of this molecule were 490 
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influenced/improved in the nematode,) preventing H. pylori 491 
infection.  492 
Conclusions 493 
Fucoidan from Undaria pinnatifida had  the highest 494 
bacteriostatic and bactericidal potential against H. pylori even 495 
at low concentrations, in the range of [5-10] µg/ml. Exposure 496 
time was a determining factor reducing H. pylori to close to 4 497 
log10 cycles just after 7 days of exposure at 25 C. The in vitro 498 
antimicrobial potential of fucoidan from Undaria pinnatifida 499 
was confirmed in C. elegans, an in vivo model for infection. For 500 
C. elegans fed H. pylori, supplementation of the media with 501 
fucoidan (100 µg/ml) increased the C. elegans lifespan from 10 502 
(NGM) to 26 days (NGM+fucoidan). These results open a new 503 
promising line of research regarding the development of 504 
nutraceutical ingredients derived from fucoidan as 505 
complementary therapies to be applied in H. pylori infection 506 
treatment. The beneficial effects associated to this algae 507 
ingredient are being extensively reported [2010-2020] and it is 508 
important to highlight the future application (food 509 
preservation, pharmaceutical, biotechnological, and medicinal) 510 
of this compound as a sustainable and effective alternative 511 
antimicrobial answering the demand of the WHO regarding 512 
the urgent need for agents  against concerning antibiotic 513 
resistant pathogens.  514 
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